Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2017—Enzo Life Sciences introduced the PlaqPro Lp-PLA2 assay, a colorimetric readout assay that measures the activity of Lp-PLA2 in serum samples. The assay is designed to run on automated chemistry analyzers. Included in the kit are ready-to-use calibration standards and QC controls in order to measure a wide analytical range of 0.0–400.0 nmol/min/mL of Lp-PLA2 activity.
January 2017—Biotheranostics and Syapse plan to integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s global partner program, which aims to leverage strong collaborators toward an integrative approach to precision medicine.
January 2017—Becton Dickinson launched its next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus, and group A strep, with new traceability and secure patient health record documentation features and functionality.
January 2017—EntroGen launched its Leukemia Translocation Panel, a multiplexed, one-step RT-PCR assay that detects 10 variants in six common leukemia-associated translocations simultaneously from total RNA isolated from blood or bone marrow. The assay is compatible with several leading multichannel real-time PCR instruments capable of detecting four commonly used fluorescent probes and produces results in 90 minutes.
November 2016—Siemens Healthineers received FDA 510(k) clearance for its Xprecia Stride Coagulation Analyzer, a handheld, portable coagulation analyzer designed to deliver fast, reliable prothrombin time international normalized ratio testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin.
November 2016—Alere announced it has achieved in vitro diagnostic CE marking in Europe for its Alere Reader, a diagnostic analyzer that can be used in point-of-care and laboratory settings. The Alere Reader will be available initially for use with the Alere BinNow Legionella and Streptococcus pneumonia antigen cards, with other lateral flow applications and assays to follow.
November 2016—Cancer diagnostics and digital pathology workflow solution provider Inspirata has acquired the assets of Boston-based Precision Medicine Network. The acquisition includes Crosswalk Insight: Oncology, a precision medicine decision-support platform.
November 2016—Thermo Fisher Scientific launched the Applied Biosystems TaqPath ProAmp PCR Master Mix. The mixes are developed for high-throughput genotyping and copy number variation protocols requiring accurate results from samples containing PCR inhibitors and are designed to deliver sensitive and reproducible results from genomic DNA targets.
November 2016—Olympus announced that the American Urological Association, together with the Society of Urologic Oncology, included the Olympus Narrow Band Imaging (NBI) technology in its newly released guideline for the diagnosis and treatment of non-muscle invasive bladder cancer.
November 2016—Qiagen launched its Paxgene Blood ccfDNA Tube for venous whole blood collection and room temperature stabilization of in vivo circulating cell-free DNA profiles.
